摘要
Currently, there is still no effective curative treatment for the development of late-stage liver fibrosis. Here, we have illustrated that TB001, a dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist with higher affinity towards GCGR, could retard the progression of liver fibrosis in various rodent models, with remarkable potency, selectivity, extended half-life and low toxicity. Four types of liver fibrosis animal models which were induced by CCl4, alpha-naphthyl-isothiocy-anate (ANIT), bile duct ligation (BDL) and Schistosoma japonicum were used in our study. We found that TB001 treatment dose-dependently significantly attenuated liver injury and collagen accumulation in these animal models. In addition to decreased levels of extracellular matrix (ECM) accumulation during hepatic injury, activation of hepatic stellate cells was also inhibited via suppression of TGF-beta expression as well as downstream Smad signaling pathways particularly in CCl4-and S. japonicum-induced liver fibrosis. Moreover, TB001 attenuated liver fibrosis through blocking downstream activation of proinflammatory nuclear factor kappa B/NF-kappa-B inhibitor alpha (NF kappa B/IKB alpha pathways as well as c-Jun N-terminal kinase (JNK)-dependent induction of hepatocyte apoptosis. Furthermore, GLP-1R and/or GCGR knock-down results represented GCGR played an important role in ameliorating CCl4-induced hepatic fibrosis. Therefore, TB001 can be used as a promising therapeutic candidate for the treatment of multiple causes of hepatic fibrosis demonstrated by our extensive pre-clinical evaluation of TB001.
学科与关键词
- Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-β/SMAD signalingSong, Yu; Wei, Jiayi; Li, Rong; Fu, Ruifeng; Han, Pei; Wang, Heming; Zhang, Guangcong; Li, Shuyu; Chen, Sinuo; Liu, Zhiyong; Zhao, Yicheng; Zhu, Changfeng; Zhu, Jimin; Zhang, Shuncai; Pei, Hao; Cheng, Jiefei; Wu, Jian; Dong, Ling*; Song, Guangqi*; Shen, Xizhong*; Yao, Qunyan*Hepatology, 2023, 78(5): 1433-1447.被引 6
- Glaucocalyxin A attenuates carbon tetrachloride-induced liver fibrosis and improves the associated gut microbiota imbalanceQu, Ru; Zhang, Wang; Ma, Zhuang; Ma, Qianwen; Chen, Mingju; Lan, Tian; Zhou, Lin; Hu, Xuguang*Chemical Biology and Drug Design, 2023, 102(1): 51-64.
- Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2Song, Zhenghui; Liu, Xinhui; Zhang, Wan; Luo, Yue; Xiao, Hua; Liu, Yun; Dai, Guanqi; Hong, Jian*; Li, Aimin*Journal of Translational Medicine, 2022, 20(1): 157.被引 6
